Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sexually Transmitted Infections01:26

Sexually Transmitted Infections

427
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
427
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

4.3K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
4.3K
Bacterial Phylum Chlamydiae01:29

Bacterial Phylum Chlamydiae

124
The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic...
124
Glaucoma: Overview01:25

Glaucoma: Overview

796
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
796
Trachea01:22

Trachea

2.8K
The trachea, commonly known as the windpipe, is a vital part of the human respiratory system. It serves as a passageway for air to travel between the larynx and the bronchi, allowing oxygen to reach the lungs. Let's explore its anatomical features, dimensions, layers of the tracheal wall, associated muscles, and the functions of its parts.
Anatomical Features:
Location: About half of the trachea is situated in the neck, anterior to the esophagus, and extends from the larynx (at the level of...
2.8K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

728
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
728

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A snapshot of selected neglected tropical disease research using the World Health Organization International Clinical Trials Registry Platform database, 1999-2023.

PLoS neglected tropical diseases·2026
Same author

Advancing health-care access to optimise health and quality of life for children and young people with Down syndrome worldwide.

The Lancet. Child & adolescent health·2026
Same author

Strengthening health-care pathways for people with Down syndrome.

The lancet. Healthy longevity·2026
Same author

Challenges, barriers and opportunities for neglected tropical disease programs of conflict-affected African countries.

International health·2026
Same author

Neglected tropical diseases in conflict-related humanitarian emergency settings: a systematic review of the literature.

International health·2026
Same author

Evaluation of a face-washing behaviour change intervention for trachoma prevention in Oromia, Ethiopia (Stronger SAFE): secondary outcomes of a cluster-randomised controlled trial.

The Lancet. Global health·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Sep 20, 2025

A Human Fallopian Tube Model for Investigation of C. trachomatis Infections
09:11

A Human Fallopian Tube Model for Investigation of C. trachomatis Infections

Published on: August 11, 2012

13.1K

Trachoma.

Esmael Habtamu1, Emma M Harding-Esch2, Katie Greenland3

  • 1Clinical Research Department, London School of Hygiene & Tropical Medicine, London, UK; Eyu-Ethiopia, Bahir Dar, Ethiopia; Department of Ophthalmology, College of Medicine and Health Science, Bahir Dar University, Bahir Dar, Ethiopia.

Lancet (London, England)
|May 24, 2025
PubMed
Summary
This summary is machine-generated.

Trachoma, a leading cause of infectious blindness, requires continued efforts for global elimination by 2030. Novel strategies are needed to address persistent active trachoma and achieve the World Health Organization

More Related Videos

Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

13.0K
Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction
07:30

Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction

Published on: October 13, 2017

11.2K

Related Experiment Videos

Last Updated: Sep 20, 2025

A Human Fallopian Tube Model for Investigation of C. trachomatis Infections
09:11

A Human Fallopian Tube Model for Investigation of C. trachomatis Infections

Published on: August 11, 2012

13.1K
Forward Genetic Approaches in Chlamydia trachomatis
09:03

Forward Genetic Approaches in Chlamydia trachomatis

Published on: October 23, 2013

13.0K
Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction
07:30

Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction

Published on: October 13, 2017

11.2K

Area of Science:

  • Ophthalmology
  • Infectious Diseases
  • Public Health

Background:

  • Trachoma is the leading infectious cause of blindness globally and a major focus for the World Health Organization's 2030 elimination goal.
  • It is caused by repeated Chlamydia trachomatis infections in childhood, leading to conjunctival scarring and potentially irreversible vision loss.
  • Affected populations are often in impoverished, rural areas with limited access to water and sanitation, disproportionately impacting women and children.

Purpose of the Study:

  • To review the global progress and challenges in eliminating trachoma as a public health problem.
  • To highlight the effectiveness of the SAFE strategy (Surgery, Antibiotics, Facial cleanliness, Environmental improvement).
  • To identify the need for new or intensified approaches to combat persistent and recurring trachoma.

Main Methods:

  • The study is a review of the current status of trachoma elimination programs worldwide.
  • It analyzes the impact and success of the SAFE strategy over the past two decades.
  • It identifies areas with persistent or recrudescent active trachoma.

Main Results:

  • The SAFE strategy has led to considerable success, with 21 countries eliminating trachoma by December 2024.
  • Several other countries are on track to meet elimination targets soon.
  • However, challenges remain due to persistent and recrudescent active trachoma in certain populations.

Conclusions:

  • While significant progress has been made, the 2030 global trachoma elimination target faces challenges.
  • Continued success requires the development and implementation of novel or intensified interventions.
  • Accelerating elimination efforts is crucial in settings with persistent disease.